Voriconazole Sandoz 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

voriconazole sandoz 50 mg

sandoz - københavn - vorikonazol - tablett, filmdrasjert - 50 mg

Voriconazole Sandoz 200 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

voriconazole sandoz 200 mg

sandoz - københavn - vorikonazol - tablett, filmdrasjert - 200 mg

Vantobra (previously Tobramycin PARI) ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

vantobra (previously tobramycin pari)

pari pharma gmbh - tobramycin - respiratory tract infections; cystic fibrosis - antibakterielle midler for systemisk bruk, - vantobra er indisert for behandling av kronisk lunge infeksjon på grunn av pseudomonas aeruginosa hos pasienter i alderen 6 år og voksne med cystisk fibrose (cf). det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Diflucan 150 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

diflucan 150 mg

orifarm as - flukonazol - kapsel, hard - 150 mg

Voriconazole Fresenius Kabi 200 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

voriconazole fresenius kabi 200 mg

fresenius kabi norge as - vorikonazol - pulver til infusjonsvæske, oppløsning - 200 mg

Diflucan 40 mg/ ml নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

diflucan 40 mg/ ml

2care4 aps - flukonazol - pulver til mikstur, suspensjon - 40 mg/ ml

Bramitob 300 mg/4 ml নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

bramitob 300 mg/4 ml

chiesi farmaceutici s.p.a. - tobramycin - inhalasjonsvæske til nebulisator, oppløsning - 300 mg/4 ml

Nyvigan kombipakning 100000 IE/ g / 100000 IE নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

nyvigan kombipakning 100000 ie/ g / 100000 ie

avia pharma ab - nystatin - salve, vaginaltablett - 100000 ie/ g / 100000 ie

Inaqovi ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

inaqovi

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemi, myeloid - antineoplastiske midler - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Vanflyta ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.